NewAmsterdam Pharma Company N.V.
NAMSW
Updated: 23/09/2026, 05:07:50
NewAmsterdam Pharma Company N.V. is a biopharmaceutical firm currently in the clinical development phase, committed to enhancing therapeutic options for individuals living with metabolic diseases. The company's primary experimental treatment, obicetrapib, is an innovative, selective agent designed to inhibit Cholesteryl Ester Transfer Protein (CETP). Clinical trials have shown this compound to be effective in both lowering "bad" low-density lipoprotein cholesterol (LDL-C) and significantly elevating "good" high-density lipoprotein cholesterol (HDL-C) simultaneously. Founded in 2019, this Dutch company maintains its headquarters in Naarden.
No summaries found.
- Share price
- $11.49
- Market cap
- $2.46B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Michael Harvey Davidson Facp.
- Employees
- 100
- IPO date
- 10/02/2021
- Beta
- 0.11
- Last dividend
- $0.00
- Day range
- $11.49 – $24.41
- 52-week range
- $11.37 – $30.45
- 1-day performance
- 0.00%
- 1-year performance
- 1.06%
- Current drawdown (1Y)
- -62.27%
- CIK
- 0001936258
- CUSIP
- N/A
- ISIN
- NL00150012K9
- Created
- 07/12/2025, 05:23:51
- Last update
- 23/09/2026, 05:07:50
Track NewAmsterdam Pharma Company N.V. with an AI analyst
See which prediction-market events move NAMSW, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
No news found for this symbol.